Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Accounting ...
Vericel Corporation. (VCEL) Q4 2021 Earnings Conference Call February 24, 2022, 08:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investors Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conferenc...
The following slide deck was published by Vericel Corporation in conjunction with their 2021 Q4 earnings call. For further details see: Vericel Corporation 2021 Q4 - Results - Earnings Call Presentation
Vericel press release (NASDAQ:VCEL): Q4 GAAP EPS of $0.09 misses by $0.05. Revenue of $47.6M (+5.3% Y/Y) misses by $0.49M. Gross margin of 72%, compared to 74% in the fourth quarter of 2020. Non-GAAP adjusted EBITDA of $12.8 million, compared to $16.0 million in the fourth quarter of 2020. Op...
Full-Year 2021 Total Revenue Growth of 26% Full-Year 2022 Total Revenue Guidance of $178 to $189 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapi...
Vericel (NASDAQ:VCEL) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $0.14 (-44.0% Y/Y) and the consensus Revenue Estimate is $48.09M (+6.4% Y/Y). Over the last 2 years, VCEL has beaten EPS estimates 75% of the time a...
The following slide deck was published by Vericel Corporation in conjunction with this event. For further details see: Vericel (VCEL) Presents at the 40th Annual J.P. Morgan Healthcare Conference - Slideshow
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial results and busi...
Vericel Corporation (NASDAQ:VCEL) entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts. The company said the new facility will...
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy m...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...